CSI Announces Marketing Agreement With Anesthesia Equipment Manufacturer, Royal Medical Co., Ltd

Business Wire, June 13, 2001

MILWAUKEE--(BUSINESS WIRE)--June 13, 2001

CRITICARE SYSTEMS, INC. (NASDAQ-NMS: CXIM) today announced it will enter the anesthesia equipment market in fiscal Q1 (July-September, 2001) through the integration of its new 5-agent solid state gas analyzer and Poet IQ Gas Monitor into Royal Medical's established line of anesthesia equipment. A new CSI division has been created to manage this program which will allow participation in an estimated $2 billion worldwide market. The Q1 introduction will focus on international applications with domestic availability anticipated to be late 2001.

Criticare president and CEO Emil Soika stated, "CSI is well positioned to address this market with its proprietary gas technology resulting in a high performance system at an attractive price point. In the coming year, the company expects to introduce a number of different configurations of its new gas measurement products for both branded and OEM applications."

CSI (www.csiusa.com) designs, manufactures, and markets cost-effective patient monitoring systems and noninvasive sensors for a wide range of hospitals and alternate health care environments throughout the world.

This press release contains forward-looking statements. Such statements refer to the company's beliefs and expectations. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described. Such uncertainties include, but are not limited to, the timely completion of new products or new manufacturing strategies, regulatory approvals for new products, the risk of new and better technologies, risks relating to international markets, as well as general conditions and competition in the company's markets. Other risks are set forth in CSI's reports and documents filed from time to time with the Securities and Exchange Commission.